A securities class action has been filed against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NASDAQ: BBNX) and certain senior officers on behalf of persons and entities who purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”).

The action, Holtzman v. Beta Bionics, Inc., et al., Case No. 2:26-cv-09999, was filed on September 4, 2026 in the U.S. District Court for the Central District of California and alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder.

If you acquired Beta Bionics common stock during the Class Period and suffered a financial loss, contact Kehoe Law Firm to discuss your legal rights without cost or obligation.

What Does the Beta Bionics Securities Class Action Allege?

The complaint alleges that, throughout the Class Period, Defendants repeatedly assured investors that the FDA’s regulatory concerns expressed in the Form 483 related only to a minor difference in regulatory interpretation, not the underlying safety of their flagship iLet device, and that all back-filed reports were entirely benign.

The complaint further alleges that Defendants continued to misleadingly reassure investors and deny any fundamental concerns with iLet as more information emerged showing the back-filed complaints were less benign than previously reported, and, thus, that the FDA’s objections went to the heart of iLet’s safety. The complaint alleges that these statements were false and misleading because:

• The FDA had raised serious issues concerning iLet itself, including allegations that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events;
• The Form 483 identified more than 18,000 unreported complaints from iLet users, including numerous allegedly life-threatening hypoglycemic events that the Company had failed to investigate or report to the FDA;
• Hundreds of complaints allegedly involved life-threatening safety events requiring hospitalization, contrary to defendants’ statements characterizing the back-filed complaints as benign or not requiring medical intervention; and
• The complaint alleges that defendants failed to accurately describe the scope and severity of the FDA’s observations, which made remediation much more complex and extensive than defendants indicated to investors.

The Corrective Disclosures and BBNX Stock Declines

The complaint alleges that the truth about defendants’ fraud was revealed through corrective disclosures made on and between January 8, 2026 and February 24, 2026.

According to the complaint, Beta Bionics common stock fell from $31.99 per share to $20.14 per share on January 9, 2026, a 37% decline. Following the Company’s January 30, 2026 Form 8-K disclosure that it had received an FDA warning letter connected to the earlier Form 483, the stock declined from $14.79 per share to $13.83 per share.

Beta Bionics Investors: Contact Kehoe Law Firm

Investors who purchased or otherwise acquired Beta Bionics common stock during the Class Period and suffered financial losses are encouraged to complete Kehoe Law Firm’s confidential Stockholder Information Request Form or send us a message to discuss their legal rights.

For a free, no-obligation legal evaluation, contact:

Michael Yarnoff, Esq.
(215) 792-6676, Ext. 804
[email protected]
[email protected]

Lead Plaintiff Deadline: November 3, 2026. Investors who wish to seek appointment as lead plaintiff must do so by November 3, 2026. Investors do not need to seek appointment as lead plaintiff to remain potential members of the proposed class or to be eligible to share in any potential recovery.

About Kehoe Law Firm, P.C.

Kehoe Law Firm, P.C. is a nationally recognized, plaintiff-side class action law firm representing investors, consumers, and employees in matters involving securities fraud, corporate misconduct, mergers and acquisitions, antitrust violations, whistleblower claims, data breaches, consumer fraud, employment law violations, and retirement-plan mismanagement. Its attorneys have served as lead or co-lead counsel in major securities cases, recovering more than $10 billion for institutional and individual investors.

Kehoe Law Firm’s class action legal services are provided on a contingency-fee basis, meaning plaintiffs are not responsible for attorneys’ fees or litigation expenses. Any request for attorneys’ fees and expenses will be subject to court approval.

PHONE

Tel: 215-792-6676

EMAIL

[email protected]